{"entity":{"id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","aka":[],"tldr":"One shot for girls and a mail-in swab for women could hit the WHO 90-70-90 targets at a fraction of the cost of the traditional three-dose, clinic-based model.","summary":"KEN SHE showed 97.5% single-dose efficacy; self-sampled HPV PCR matches clinician sampling; thermal ablation enables screen-and-treat. Modelling (Lancet Global Health 2024) suggests single-dose schedules could make elimination feasible in most low-income settings within the century, but coverage of girls is still ~27% globally.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03675256: KEN SHE (single-dose HPV vaccine)","url":"https://clinicaltrials.gov/study/NCT03675256"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine","hpv-testing","precancer-ablation"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ken-she"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Countries adopting single-dose HPV vaccination plus HPV self-sampling with screen-and-treat reach 90% vaccination and 70% screening coverage a decade earlier than those on multi-dose, cytology-based programmes.","rationale":"Cost per protected girl halves; self-sampling removes clinic access and stigma barriers; ablation removes the surgeon bottleneck.","test":"Country-level comparisons within the WHO Cervical Cancer Elimination Initiative dashboards, and cluster-randomised implementation trials (e.g., in Kenya, Rwanda, India).","maturity":"being-tested-at-scale"},"route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/"},{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/"}],"drug":[{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/"},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/"}],"trial":[{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/"},{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"}],"paper":[{"id":"paper-hpv-vaccine-sweden-nejm-2020","kind":"paper","name":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","route":"/key-papers/paper-hpv-vaccine-sweden-nejm-2020/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"}]}}